• Climb Bio will present preliminary Phase 1b budoprutug data in immune thrombocytopenia at the American Society of Hematology meeting Dec. 13, 2026.
• The ongoing trial evaluates the anti-CD19 antibody in previously treated adults with primary immune thrombocytopenia.
• The presentation will cover safety, B-cell depletion and platelet data across all three dose cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869630) on November 04, 2026, and is solely responsible for the information contained therein.